Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders

Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders

NEW YORK & LONDON & PARIS–(BUSINESS WIRE)–
Regulatory News:

Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, today announced the results of its 2020 annual general meeting of shareholders, which was held on December 9, 2020, in Hong Kong.

At the annual general meeting, the required number of shareholders of the Company:

  1. re-elected all of the Company’s current directors, namely Mr. Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Mr. Charles Bathurst, Dr. Mirko Scherer, Dr. Justin Wu and Professor Douglas Arner as directors of the Company until the Company’s next annual general meeting of shareholders or until their respective successors are duly appointed and qualified; and
  2. approved, ratified and confirmed the re-appointment of Marcum Bernstein & Pinchuk LLP as the Company’s independent auditors for the year ending December 31, 2020 and authorized the Board of Directors to fix the remuneration of the auditors.

About Aptorum Group Limited

Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) is a pharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). Aptorum’s pipeline is enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through programs such as the systematic screening of existing approved drug molecules and microbiome-based research platform for treatments of metabolic diseases. In addition to the above main focus, the Company is pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. Aptorum also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations.

These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020.

As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

This press release is provided “as is” without any representation or warranty of any kind.

Inquiries:

Aptorum Group Limited

Investor Relations Department

[email protected]

+44 20 80929299

Redchip – Financial Communications United States

Investor Relations

Dave Gentry

[email protected]

+1 407 491 4498

Actifin – Financial Communications Europe

Investor Relations

Ghislaine Gasparetto

[email protected]

+33 1 56 88 11 22

KEYWORDS: North America France United States United Kingdom Europe New York

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo

Absolute Software Reports Annual Shareholders Meeting Voting Results

Absolute Software Reports Annual Shareholders Meeting Voting Results

VANCOUVER, British Columbia–(BUSINESS WIRE)–Absolute Software™ (TSX: ABST) (Nasdaq: ABST), a leader in Endpoint Resilience™ solutions, today announced that at its annual general meeting of shareholders held virtually on December 9, 2020, each of the six nominees listed below, and discussed further in Absolute’s management information circular dated November 6, 2020, were elected as Directors.

The voting results for each Director are as follows:

Director

Votes For (#)

Votes For (%)

Daniel Ryan

24,170,171

92.56%

Lynn Atchison

26,029,717

99.69%

Gregory Monahan

24,157,498

92.52%

Salvatore Visca

24,060,554

92.14%

Gerhard Watzinger

23,568,449

90.26%

Christy Wyatt

23,770,881

91.04%

Absolute’s shareholders also voted in favour of the re-appointment of Deloitte LLP as Absolute’s auditors.

Detailed voting results will be posted under Absolute’s profile on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

About Absolute Software

Absolute Software is a leader in Endpoint Resilience solutions and the industry’s only undeletable defense platform embedded in over a half-billion devices. Enabling a permanent digital tether between the endpoint and the enterprise who distributed it, Absolute provides IT and Security organizations with complete connectivity, visibility, and control, whether a device is on or off the corporate network, and empowers them with Self-Healing Endpoint™ security to ensure mission-critical apps remain healthy and deliver intended value.

©2020 Absolute Software Corporation. All rights reserved. ABSOLUTE and the ABSOLUTE logo are registered trademarks of Absolute Software Corporation in the United States and/or other countries. Other names or logos mentioned herein may be the trademarks of Absolute or their respective owners. The absence of the symbols ™ and ® in proximity to each trademark, or at all, herein is not a disclaimer of ownership of the related trademark.

Investor Relations

Joo-Hun Kim

[email protected]

212-868-6760

Media Relations

Becki Levine

[email protected]

858-524-9443

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Software Technology Data Management Security

MEDIA:

Logo
Logo

Velodyne Lidar Introduces Solid State Sensor for Autonomous Mobile Robotics and Last-Mile Delivery

Velodyne Lidar Introduces Solid State Sensor for Autonomous Mobile Robotics and Last-Mile Delivery

Velarray M1600 Provides Advanced Perception for Rapidly Growing Autonomous Robot Market

SAN JOSE, Calif.–(BUSINESS WIRE)–Velodyne Lidar, Inc. (Nasdaq: VLDR) today announced the Velarray M1600, an innovative solid state lidar sensor designed to serve mobile robotic applications. The sensor is the latest in a new line of Velarray products and first in the new M-series. It is built using Velodyne’s breakthrough proprietary micro-lidar array architecture (MLA) and leverages Velodyne’s manufacturing partnerships for cost optimization and high-volume production.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005273/en/

Velodyne Lidar’s Velarray M1600 is an innovative solid state lidar sensor designed to serve mobile robotic applications. (Photo: Velodyne Lidar, Inc.)

Velodyne Lidar’s Velarray M1600 is an innovative solid state lidar sensor designed to serve mobile robotic applications. (Photo: Velodyne Lidar, Inc.)

The Velarray M1600 enables touchless mobile and last-mile delivery robots to operate autonomously and safely, without human intervention. The COVID-19 pandemic has driven up the usage of online shopping and delivery services for food, medications, consumer and commercial products. According to CNBC, the U.S. Thanksgiving, Black Friday and Cyber Monday holiday shopping period broke all records for online shopping and the usage of delivery services, in part due to the COVID-19 pandemic. Adobe Analytics predicts $184 billion will be spent online the entire holiday period, a 30 percent increase over 2019.

“The Velarray M1600 lidar sensor is the latest proof point for Velodyne’s innovation track record,” said Anand Gopalan, Velodyne Lidar CEO. “The sensor was designed for high volume mobile robotic applications with direct input from robotics and last-mile delivery customers. This durable and compact sensor can be deployed in a wide variety of environments and weather conditions allowing nearly 365-day, 24/7 usage. It can provide the smart, real-time perception data required by autonomous mobile robots for safe and extended operation without human intervention.”

The Velarray M1600 provides autonomous robots with outstanding near-field perception up to 30 meters and a broad 32-degree vertical field of view, allowing them to traverse unstructured and changing environments. The sensor enables robots to safely navigate crowded urban areas and corridors for delivery and security applications. Other environments in which the Velarray M1600 will enable autonomous mobile robot operation include warehouses, retail centers, industrial plants and medical facilities. For customers seeking a perception solution package, Velodyne provides Vella software, which utilizes Velarray M1600 data for object and hazard detection, to protect roadway users including pedestrians, bicyclists and pets.

Designed for functional safety and durability, the Velarray M1600 supports autonomous mobile robots in a wide variety of challenging environmental conditions, including temperature, lighting and precipitation. Featuring a compact form factor, the sensor is well-suited for external mounting but also can be easily embedded into robotics systems. For more about lidar-enhanced robots, download Velodyne’s white paper: The Benefits of 3D Lidar for Autonomous Mobile Robots.

With the available Robot Operating System driver, the Velarray M1600 provides a user-friendly interface for developers. The sensor has modest power demands so the robot can operate longer between battery charges. Samples will be available to qualified customers with a lead time of approximately 6-8 weeks.

About Velodyne Lidar

Velodyne Lidar (NASDAQ: VLDR) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

Forward Looking Statements

Statements in this release may contain “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “can”, “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; uncertainties related to Velodyne’s estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations

Andrew Hamer

Chief Financial Officer

[email protected]

Media

Landis Communications Inc.

Sean Dowdall

(415) 286-7121

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Online Retail Technology Public Transport Transport Retail Software Logistics/Supply Chain Management Internet Mobile/Wireless Hardware Electronic Design Automation

MEDIA:

Photo
Photo
Velodyne Lidar’s Velarray M1600 is an innovative solid state lidar sensor designed to serve mobile robotic applications. (Photo: Velodyne Lidar, Inc.)
Photo
Photo
Velodyne Lidar’s Velarray M1600 lidar sensor enables touchless mobile and last-mile delivery robots to operate autonomously and safely, without human intervention. (Photo: Velodyne Lidar, Inc.)
Logo
Logo

Intuit TurboTax Live Renews Presenting Sponsorship of NFL AFC & NFC Championship Games; Adds NFL AFC & NFC Divisional Round Presenting Sponsorship

Intuit TurboTax Live Renews Presenting Sponsorship of NFL AFC & NFC Championship Games; Adds NFL AFC & NFC Divisional Round Presenting Sponsorship

NFL and Intuit Extend Agreement to serve as the League’s Official Sponsor for Financial and Accounting Software, and Tax Preparation Services

SAN DIEGO & NEW YORK–(BUSINESS WIRE)–
The National Football League (NFL) and Intuit Inc (Nasdaq: INTU), maker of TurboTax®, QuickBooks®, and Mint® today announced a renewal of their official partnership through 2022. As a part of the sponsorship, TurboTax Live will serve as the presenting sponsor of both the AFC and NFC Divisional games and continue their presenting sponsorship of the Championship Games for the 2020 NFL season. In 2019, Intuit TurboTax Live became the first-ever presenting sponsor of both the AFC and NFC Championship Games.

“We’re ecstatic to not only welcome Intuit TurboTax Live back as presenting sponsor for both AFC and NFC Championship games, but also expand the relationship to encompass our Divisional round,” said Nana-Yaw Asamoah, Vice President of Partnership Business Development for the NFL. “As a leader in financial and tax preparation products, Intuit provides platforms that NFL fans recognize and need more than ever this time of year.”

“We are thrilled to not only be continuing, but expanding our relationship with the NFL,” said Cathleen Ryan, Vice President of Marketing for Intuit’s Consumer Group. “At Intuit, we are proud to coach millions of people through their taxes and finances each year. With this sponsorship we will have the unique opportunity to reach passionate NFL fans with the tools and guidance to help them prosper during the height of tax season.”

As the presenting sponsorship of both 2020 AFC and NFC Divisional and Championship games, TurboTax Live branding will be featured during the 2020 AFC and NFC Divisional and Championship Games as well as within ancillary programming and content across league broadcast and digital media platforms. Fans can also look forward to seeing TurboTax Live return to NFL Super Bowl LV for its eighth consecutive year.

Intuit will also continue to be the NFL’s official sponsor for financial and accounting software, and tax preparation services. Intuit helps power prosperity for consumers, self-employed and small business owners finding them more money with the least amount of work, while giving them complete confidence in their actions and decisions.

As a part of the sponsorship, Intuit QuickBooks will have branded content during the NFC Championship Game on FOX, January 24, 2021. The ad will spotlight a small business and how the QuickBooks Online ecosystem helps them be more successful.

About the National Football League (NFL)

The National Football League is America’s most popular sports league, comprised of 32 franchises that compete each year to win the Super Bowl, the world’s biggest annual sporting event. Founded in 1920, the NFL developed the model for the successful modern sports league, including national and international distribution, extensive revenue sharing, competitive excellence, and strong franchises across the country.

NFL content has never been more popular across the US media landscape. According to Nielsen, 183 million people tuned into the 2019 NFL regular season representing 69 percent of all television homes and 59 percent of potential viewers in the U.S. In 2019, NFL games accounted for 42 of television’s 50 most-watched programs.

About Intuit

Intuit’s mission is to power prosperity around the world. We are a mission-driven, global financial platform company with products including TurboTax, QuickBooks, and Mint, designed to empower consumers, self-employed and small businesses to improve their financial lives. Our platform and products help customers get more money with the least amount of work, while giving them complete confidence in their actions and decisions. Our innovative ecosystem of financial management solutions serves more than 50 million customers worldwide. Please visit us for the latest news and in-depth information about Intuit and its brands and find us on social.

Alex Riethmiller, NFL

310-840-4635

Ashley McMahon, Intuit

858-215-9069

KEYWORDS: United States North America California New York

INDUSTRY KEYWORDS: Technology Sports Advertising Accounting Communications Professional Services Football Hispanic Software Consumer

MEDIA:

Adobe Reports Record Q4 and Fiscal 2020 Revenue

Adobe Reports Record Q4 and Fiscal 2020 Revenue

Company Generates Record $1.8 Billion in Operating Cash Flows During Q4; Surpasses $10 Billion in Digital Media ARR

SAN JOSE, Calif.–(BUSINESS WIRE)–
Adobe (Nasdaq:ADBE) today reported financial results for its fourth quarter and fiscal year ended Nov. 27, 2020. In its fourth quarter of fiscal year 2020, Adobe achieved record quarterly revenue of $3.42 billion, which represents 14 percent year-over-year growth. In fiscal year 2020, Adobe achieved record annual revenue of $12.87 billion, which represents 15 percent year-over-year growth.

“Adobe delivered record Q4 and FY20 revenue performance amidst an unprecedented macroeconomic environment,” said Shantanu Narayen, president and CEO, Adobe. “As the undisputed leader in three growing categories – creativity, digital documents and customer experience management – we are well-positioned to capture the massive market opportunity ahead of us in 2021 and beyond.”

“The resilience of our business, our operational discipline and ability to derive insights from real-time data has enabled us to thrive in 2020,” said John Murphy, executive vice president and CFO, Adobe. “Our record Q4 cash flow demonstrates the strength of our operating model, and we look forward to delivering strong top- and bottom-line growth in 2021.”

Segment Reporting Update

In its fourth quarter of fiscal year 2020, Adobe created a new segment called “Publishing and Advertising,” which combines the Publishing segment with Advertising Cloud, which was previously included in the Digital Experience segment. This realignment resulted from a change Adobe made in the fourth quarter to the way the company manages its Digital Experience business to better reflect the strategic shift related to Advertising Cloud and to align with our overall core value proposition of delivering on customer experience management. Advertising Cloud revenue and cost of revenue has been reclassified on the income statement from “Subscription” to “Services and other.” Financial information for fiscal years 2018, 2019 and 2020 has been revised to maintain comparability.

Fourth Quarter Fiscal Year 2020 Financial Highlights

  • Adobe achieved record quarterly revenue of $3.42 billion in its fourth quarter of fiscal year 2020, which represents 14 percent year-over-year growth. Diluted earnings per share was $4.64 on a GAAP basis, and $2.81 on a non-GAAP basis.
  • Digital Media segment revenue was $2.50 billion, which represents 20 percent year-over-year growth. Creative revenue grew to $2.08 billion and Document Cloud revenue grew to $411 million. Digital Media Annualized Recurring Revenue (“ARR”) grew to $10.18 billion exiting the quarter, a quarter-over-quarter increase of $548 million. Creative ARR grew to $8.72 billion, and Document Cloud ARR grew to $1.46 billion.
  • Digital Experience segment revenue, including Advertising Cloud revenue, was $877 million.
  • Following the segment reporting change, Digital Experience segment revenue was $819 million, representing 10 percent year-over-year growth. Digital Experience subscription revenue grew 14 percent year-over-year.
  • GAAP operating income in the fourth quarter was $1.22 billion, and non-GAAP operating income was $1.54 billion. GAAP net income was $2.25 billion, and non-GAAP net income was $1.36 billion.
  • Cash flows from operations were a record $1.78 billion.
  • Remaining Performance Obligation (“RPO”) exiting the quarter was $11.34 billion.
  • Adobe repurchased approximately 1.6 million shares during the quarter.

Fiscal Year 2020 Financial Highlights

  • Adobe achieved record annual revenue of $12.87 billion in fiscal year 2020, representing 15 percent year-over-year growth.
  • The company reported annual GAAP diluted earnings per share of $10.83 and non-GAAP diluted earnings per share of $10.10.
  • Digital Media segment revenue was $9.23 billion, representing 20 percent year-over-year growth. Creative and Document Cloud achieved record annual revenue of $7.74 billion and $1.50 billion, respectively. Digital Media ARR grew by $1.85 billion during the year.
  • Digital Experience segment revenue, including Advertising Cloud, was $3.40 billion.
  • Following the segment reporting change, Digital Experience segment revenue was $3.13 billion, representing 12 percent year-over-year growth. Digital Experience subscription revenue grew 17 percent year-over-year.
  • Operating income grew 30 percent and net income grew 78 percent year-over-year on a GAAP-basis; operating income grew 24 percent and net income grew 27 percent year-over-year on a non-GAAP basis.
  • Adobe generated a record $5.73 billion in operating cash flows during the year.
  • The company repurchased 8.0 million shares during the year, returning $3.0 billion of cash to stockholders.

A reconciliation between GAAP and non-GAAP results is provided at the end of this press release and on Adobe’s website.

Adobe Provides Fiscal Year and First Quarter 2021 Financial Targets

The following table summarizes Adobe’s fiscal year 2021 targets:

Total revenue

~$15.15 billion

Digital Media segment revenue

~19 percent year-over-year growth

Digital Media annualized recurring revenue (ARR)

~$1.75 billion of net new ARR

Digital Experience segment revenue

~19 percent year-over-year growth

Digital Experience subscription revenue

~22 percent year-over-year growth

Tax rate

GAAP: ~19 percent

Non-GAAP: ~17.5 percent

Share count

~482 million shares

Earnings per share

GAAP: ~$8.57

Non-GAAP: ~$11.20

The table below summarizes Adobe’s first quarter fiscal year 2021 targets, which factor in the following:

  • The financial impacts of the Workfront acquisition, which closed on Dec. 7 and is expected to contribute approximately $25 million to Adobe’s revenue during the first quarter, following estimated purchase accounting adjustments; and
  • The impacts of a 53-week fiscal year, with an additional week in Q1 expected to contribute approximately $240 million of total Adobe revenue and approximately $25 million of net new Digital Media ARR in the quarter.

Total revenue

~$3.75 billion

Digital Media segment revenue

~26 percent year-over-year growth

Digital Media annualized recurring revenue (ARR)

~$410 million of net new ARR

Digital Experience segment revenue

~19 percent year-over-year growth

Digital Experience subscription revenue

~22 percent year-over-year growth

Tax rate

GAAP: ~15.5 percent

Non-GAAP: ~17.5 percent

Share count

~484 million shares

Earnings per share

GAAP: ~$2.19

Non-GAAP: ~$2.78

A reconciliation between GAAP and non-GAAP targets is provided at the end of this press release.

Adobe to Webcast Earnings Conference Call

Adobe will webcast its fourth quarter fiscal year 2020 earnings conference call, together with an online financial analyst meeting, today at 8:00 a.m. Pacific Time from its investor relations website: www.adobe.com/ADBE. Earnings documents, including Adobe management’s prepared slides and an investor datasheet are posted to Adobe’s investor relations website in advance of the conference call for reference. A reconciliation between GAAP and non-GAAP earnings results and financial targets is also provided on the website.

Forward-Looking Statements Disclosure

This press release contains forward-looking statements, including those related to business momentum and strategy, the financial impacts of the Workfront acquisition, the effects of the COVID-19 pandemic on our business and results of operations, our market opportunity, market trends, current macroeconomic conditions, revenue, operating margin, seasonality, annualized recurring revenue, tax rate on a GAAP and non-GAAP basis, earnings per share on a GAAP and non-GAAP basis, and share count, all of which involve risks and uncertainties that could cause actual results to differ materially. Factors that might cause or contribute to such differences include, but are not limited to: failure to compete effectively, failure to develop, acquire, market and offer products and services that meet customer requirements, introduction of new technology, information security and privacy, potential interruptions or delays in hosted services provided by us or third parties, macroeconomic conditions and economic impact of the COVID-19 pandemic, risks associated with cyber-attacks, complex sales cycles, risks related to the timing of revenue recognition from our subscription offerings, fluctuations in subscription renewal rates, failure to realize the anticipated benefits of past or future acquisitions, failure to effectively manage critical strategic third-party business relationships, changes in accounting principles and tax regulations, uncertainty in the financial markets and economic conditions in the countries where we operate, and other various risks associated with being a multinational corporation. For a discussion of these and other risks and uncertainties, please refer to Adobe’s Annual Report on Form 10-K for our fiscal year 2019 ended Nov. 29, 2019, and Adobe’s Quarterly Reports on Form 10-Q issued in fiscal year 2020.

The financial information set forth in this press release reflects estimates based on information available at this time. These amounts could differ from actual reported amounts stated in Adobe’s Annual Report on Form 10-K for our year ended Nov. 27, 2020, which Adobe expects to file in January 2021. Adobe assumes no obligation to, and does not currently intend to, update these forward-looking statements.

About Adobe

Adobe is changing the world through digital experiences. For more information, visit www.adobe.com.

©2020 Adobe. All rights reserved. Adobe and the Adobe logo are either registered trademarks or trademarks of Adobe (or one of its subsidiaries) in the United States and/or other countries. All other trademarks are the property of their respective owners.

Condensed Consolidated Statements of Income

(In millions, except per share data; unaudited)

 

 

Three Months Ended

Year Ended

 

November 27,

2020

November 29,

2019

November 27,

2020

November 29,

2019

Revenue:

 

 

 

 

Subscription

$

3,115

 

$

2,579

 

$

11,626

 

$

9,634

 

Product

127

 

167

 

507

 

648

 

Services and other

182

 

246

 

735

 

889

 

Total revenue

3,424

 

2,992

 

12,868

 

11,171

 

 

 

 

 

 

Cost of revenue:

 

 

 

 

Subscription

283

 

245

 

1,108

 

926

 

Product

10

 

9

 

36

 

40

 

Services and other

135

 

198

 

578

 

707

 

Total cost of revenue

428

 

452

 

1,722

 

1,673

 

 

 

 

 

 

Gross profit

2,996

 

2,540

 

11,146

 

9,498

 

 

 

 

 

 

Operating expenses:

 

 

 

 

Research and development

558

 

500

 

2,188

 

1,930

 

Sales and marketing

941

 

801

 

3,591

 

3,244

 

General and administrative

243

 

226

 

968

 

881

 

Amortization of intangibles

39

 

43

 

162

 

175

 

Total operating expenses

1,781

 

1,570

 

6,909

 

6,230

 

 

 

 

 

 

Operating income

1,215

 

970

 

4,237

 

3,268

 

 

 

 

 

 

Non-operating income (expense):

 

 

 

 

Interest expense

(27

)

(37

)

(116

)

(157

)

Investment gains (losses), net

6

 

5

 

13

 

52

 

Other income (expense), net

3

 

19

 

42

 

42

 

Total non-operating income (expense), net

(18

)

(13

)

(61

)

(63

)

Income before income taxes

1,197

 

957

 

4,176

 

3,205

 

Provision for (benefit from) income taxes

(1,053

)

105

 

(1,084

)

254

 

Net income

$

2,250

 

$

852

 

$

5,260

 

$

2,951

 

Basic net income per share

$

4.69

 

$

1.76

 

$

10.94

 

$

6.07

 

Shares used to compute basic net income per share

479

 

484

 

481

 

486

 

Diluted net income per share

$

4.64

 

$

1.74

 

$

10.83

 

$

6.00

 

Shares used to compute diluted net income per share

484

 

489

 

485

 

492

 

Condensed Consolidated Balance Sheets

(In millions; unaudited)

 

 

November 27,

2020

November 29,

2019

ASSETS

 

 

 

 

 

Current assets:

 

 

Cash and cash equivalents

$

4,478

 

$

2,650

 

Short-term investments

1,514

 

1,527

 

Trade receivables, net of allowances for doubtful accounts of $21 and $10, respectively

1,398

 

1,535

 

Prepaid expenses and other current assets

756

 

783

 

Total current assets

8,146

 

6,495

 

 

 

 

Property and equipment, net

1,517

 

1,293

 

Operating lease right-of-use assets, net

487

 

 

Goodwill

10,742

 

10,691

 

Other intangibles, net

1,359

 

1,721

 

Deferred income taxes

1,370

 

 

Other assets

663

 

562

 

Total assets

$

24,284

 

$

20,762

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities:

 

 

Trade payables

$

306

 

$

209

 

Accrued expenses

1,422

 

1,399

 

Debt

 

3,149

 

Deferred revenue

3,629

 

3,378

 

Income taxes payable

63

 

56

 

Operating lease liabilities

92

 

 

Total current liabilities

5,512

 

8,191

 

 

 

 

Long-term liabilities:

 

 

Debt

4,117

 

989

 

Deferred revenue

130

 

123

 

Income taxes payable

529

 

616

 

Deferred income taxes

10

 

140

 

Operating lease liabilities

499

 

 

Other liabilities

223

 

173

 

Total liabilities

11,020

 

10,232

 

 

 

 

Stockholders’ equity:

 

 

Preferred stock

 

 

Common stock

 

 

Additional paid-in-capital

7,357

 

6,504

 

Retained earnings

19,611

 

14,829

 

Accumulated other comprehensive income (loss)

(158

)

(188

)

Treasury stock, at cost

(13,546

)

(10,615

)

Total stockholders’ equity

13,264

 

10,530

 

Total liabilities and stockholders’ equity

$

24,284

 

$

20,762

 

Condensed Consolidated Statements of Cash Flows

(In millions; unaudited)

 

 

Three Months Ended

 

November 27,

2020

November 29,

2019

Cash flows from operating activities:

 

 

Net income

$

2,250

 

$

852

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

Depreciation, amortization and accretion

190

 

188

 

Stock-based compensation

233

 

203

 

Unrealized investment (gains) losses, net

(7

)

(4

)

Other non-cash adjustments

(1,192

)

15

 

Changes in deferred revenue

310

 

245

 

Changes in other operating assets and liabilities

(2

)

(123

)

Net cash provided by operating activities

1,782

 

1,376

 

 

 

 

Cash flows from investing activities:

 

 

Purchases, sales and maturities of short-term investments, net

(22

)

(85

)

Purchases of property and equipment

(103

)

(94

)

Purchases and sales of long-term investments, intangibles and other assets, net

(6

)

12

 

Acquisitions, net of cash acquired

 

(1

)

Net cash used for investing activities

(131

)

(168

)

 

 

 

Cash flows from financing activities:

 

 

Purchases of treasury stock

(850

)

(750

)

Taxes paid related to net share settlement of equity awards, net of proceeds from treasury stock re-issuances

(82

)

(27

)

Other financing activities, net

(8

)

11

 

Net cash used for financing activities

(940

)

(766

)

Effect of exchange rate changes on cash and cash equivalents

 

(1

)

Net increase in cash and cash equivalents

711

 

441

 

Cash and cash equivalents at beginning of period

3,767

 

2,209

 

Cash and cash equivalents at end of period

$

4,478

 

$

2,650

 

Non-GAAP Results

(In millions, except per share data)

The following table shows Adobe’s GAAP results reconciled to non-GAAP results included in this release.

 

 

Three Months Ended

Year Ended

 

November 27,

2020

November 29,

2019

August 28,

2020

November 27,

2020

November 29,

2019

Operating income:

 

 

 

 

 

 

 

 

 

 

 

GAAP operating income

$

1,215

 

$

970

 

$

1,069

 

$

4,237

 

$

3,268

 

Stock-based and deferred compensation expense

239

 

208

 

244

 

924

 

798

 

Amortization of intangibles

84

 

96

 

90

 

360

 

395

 

Non-GAAP operating income

$

1,538

 

$

1,274

 

$

1,403

 

$

5,521

 

$

4,461

 

 

 

 

 

 

 

Net income:

 

 

 

 

 

 

 

 

 

 

 

GAAP net income

$

2,250

 

$

852

 

$

955

 

$

5,260

 

$

2,951

 

Stock-based and deferred compensation expense

239

 

208

 

244

 

924

 

798

 

Amortization of intangibles

84

 

96

 

90

 

360

 

395

 

Investment (gains) losses, net

(6

)

(5

)

(10

)

(13

)

(52

)

Income tax adjustments

(1,204

)

(33

)

(33

)

(1,628

)

(224

)

Non-GAAP net income

$

1,363

 

$

1,118

 

$

1,246

 

$

4,903

 

$

3,868

 

 

 

 

 

 

 

Diluted net income per share:

 

 

 

 

 

 

 

 

 

 

 

GAAP diluted net income per share

$

4.64

 

$

1.74

 

$

1.97

 

$

10.83

 

$

6.00

 

Stock-based and deferred compensation expense

0.49

 

0.43

 

0.50

 

1.90

 

1.62

 

Amortization of intangibles

0.17

 

0.20

 

0.19

 

0.74

 

0.80

 

Investment (gains) losses, net

(0.01

)

(0.01

)

(0.02

)

(0.03

)

(0.10

)

Income tax adjustments

(2.48

)

(0.07

)

(0.07

)

(3.34

)

(0.45

)

Non-GAAP diluted net income per share

$

2.81

 

$

2.29

 

$

2.57

 

$

10.10

 

$

7.87

 

 

 

 

 

 

 

Shares used in computing diluted net income per share

484

 

489

 

485

 

485

 

492

The following table shows Adobe’s GAAP fourth quarter fiscal year 2020 tax rate reconciled to the non-GAAP tax rate included in this release.

 

Fourth Quarter

Fiscal 2020

Effective income tax rate:

 

 

 

GAAP effective income tax rate

(88.0

)

%

Trading structure change

95.0

 

 

Income tax adjustments

4.5

 

 

Stock-based and deferred compensation expense

(1.1

)

 

Amortization of intangibles

(0.4

)

 

Non-GAAP effective income tax rate

10.0

 

%

Reconciliation of GAAP to Non-GAAP Financial Targets

(Shares in millions)

The following tables show Adobe’s first quarter fiscal year 2021 financial targets reconciled to the non-GAAP financial targets included in this release.

 

First Quarter

Fiscal 2021

Diluted net income per share:

 

 

 

GAAP diluted net income per share

$

2.19

 

 

Stock-based and deferred compensation expense

 

0.60

 

 

Amortization of intangibles

 

0.18

 

 

Income tax adjustments

 

(0.19

)

 

Non-GAAP diluted net income per share

$

2.78

 

 

 

 

Shares used to compute diluted net income per share

484

 

 

 

 

First Quarter

Fiscal 2021

 

Effective income tax rate:

 

 

 

GAAP effective income tax rate

 

15.5

 

%

Stock-based and deferred compensation expense

 

(0.9

)

 

Amortization of intangibles

 

(0.1

)

 

Income tax adjustments

 

3.0

 

 

Non-GAAP effective income tax rate

 

17.5

 

%

(Shares in millions)

The following tables show Adobe’s annual fiscal year 2021 financial targets reconciled to the non-GAAP financial targets included in this release.

 

Fiscal Year 2021

Diluted net income per share:

 

 

 

GAAP diluted net income per share

$

8.57

 

 

Stock-based and deferred compensation expense

 

2.31

 

 

Amortization of intangibles

 

0.70

 

 

Income tax adjustments

 

(0.38

)

 

Non-GAAP diluted net income per share

$

11.20

 

 

 

 

Shares used to compute diluted net income per share

482

 

 

 

 

Fiscal Year 2021

 

Effective income tax rate:

 

 

 

GAAP effective income tax rate

 

19.0

 

%

Stock-based and deferred compensation expense

 

(0.9

)

 

Amortization of intangibles

 

(0.1

)

 

Income tax adjustments

 

(0.5

)

 

Non-GAAP effective income tax rate

 

17.5

 

%

Use of Non-GAAP Financial Information

Adobe continues to provide all information required in accordance with GAAP, but believes evaluating its ongoing operating results may not be as useful if an investor is limited to reviewing only GAAP financial measures. Adobe uses non-GAAP financial information to evaluate its ongoing operations and for internal planning and forecasting purposes. Adobe’s management does not itself, nor does it suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Adobe presents such non-GAAP financial measures in reporting its financial results to provide investors with an additional tool to evaluate Adobe’s operating results. Adobe believes these non-GAAP financial measures are useful because they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making. This allows institutional investors, the analyst community and others to better understand and evaluate our operating results and future prospects in the same manner as management.

Adobe’s management believes it is useful for itself and investors to review, as applicable, both GAAP information as well as non-GAAP measures, which may exclude items such as stock-based and deferred compensation expenses, restructuring and other charges, amortization of intangibles, investment gains and losses, the related tax impact of all of these items, income tax adjustments, and the income tax effect of the non-GAAP pre-tax adjustments from the provision for income taxes. Adobe uses these non-GAAP measures in order to assess the performance of Adobe’s business and for planning and forecasting in subsequent periods. Whenever such a non-GAAP measure is used, Adobe provides a reconciliation of the non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed above.

Investor Relations Contact

Jonathan Vaas

Adobe

[email protected]

Public Relations Contact

Ramona Redlingshafer

Adobe

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Technology Photography Audio/Video Software Internet

MEDIA:

Logo
Logo

MakerBot Offers Three New ABS Composite Materials from Kimya for METHOD 3D Printers

MakerBot Offers Three New ABS Composite Materials from Kimya for METHOD 3D Printers

Available through MakerBot LABS™, these new materials offer advanced properties that are ideal for manufacturing applications

BROOKLYN, N.Y.–(BUSINESS WIRE)–MakerBot, a global leader in 3D printing and subsidiary of Stratasys Ltd. (Nasdaq: SSYS), today announces that three new Kimya ABS composite materials by ARMOR have been qualified for MakerBot LABS™ for the MakerBot METHOD X® 3D printer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005245/en/

(Photo: Business Wire)

(Photo: Business Wire)

Composites are one of the most in-demand material categories for manufacturing applications due to their enhanced properties compared to unfilled thermoplastics. The new materials include Kimya ABS Kevlar for parts with high strength, abrasion-resistance, and dimensional stability; Kimya ABS-ESD, which protects against electrostatic discharges; and Kimya ABS-EC, a new and unique material that is electrically-conductive. Parts 3D printed with composite materials can often replace traditionally-manufactured parts, resulting in significant time and cost savings. ARMOR, for example, has demonstrated cost savings of up to 80% compared to traditional manufacturing methods by 3D printing tools and fixtures with the ABS Kevlar material in its own production facilities. ARMOR Group specializes in the industrial formulation of innovative materials and thin film coating and is the global market leader in the design and manufacturing of thermal transfer ribbons for printing variable traceability data on labels and flexible packaging.

With its up to 110°C heated chamber and ability to control the speed at which parts cool during the printing process, METHOD can print strong manufacturing-grade parts from advanced engineering materials more successfully than traditional desktop 3D printers. Users can also produce parts that have internal structures or complex geometries on METHOD when printing with Stratasys® SR-30™ soluble supports.

Kimya ABS Kevlar, Kimya ABS-ESD, and Kimya ABS-EC are available to print on the METHOD X 3D printer with the new MakerBot LABS GEN 2 Experimental Extruder, the latest edition of the LABS extruder. The GEN 2 Experimental Extruder is optimized to print more abrasive third-party composites and polymers for longer periods of time due to its upgraded hardened-steel components, such as the hardened gears and a metal filament switch designed to reduce wear from these materials.

“The MakerBot LABS extruder provides METHOD users access to a wide variety of 3D printing materials from third-party suppliers,” said Johan-Till Broer, VP of Product Development, MakerBot. “The three new ABS composite materials from Kimya continue our expansion into advanced engineering materials that unlock new manufacturing applications. With its up to 110°C heated chamber, METHOD is the first truly industrial 3D printing platform in its price class, delivering higher precision and strength than desktop 3D printers.”

“The ability to 3D print Kimya composites like ABS Kevlar and Carbon Fiber on the MakerBot METHOD X has given us a unique combination of tool-grade part performance and high precision in an extremely affordable and accessible package. In our own manufacturing facility, we’ve been able to replace several traditionally-manufactured parts with printed parts gaining a savings of up to 99.4% per part,” said Pierre-Antoine Pluvinage, Business Director, ARMOR 3D.

The new additions to MakerBot’s materials portfolio bring the total number of materials available for METHOD customers to 23. The new materials include:

  • Kimya ABS Kevlar – Kimya ABS Kevlar is an extremely strong yet lightweight and durable material that is known for its use in bullet proof vests and race tires. Reinforced with aramid fibers, this is a composite filament that gives finished 3D printed parts greater strength and dimensional stability. The addition of aramid fibers reduces shrinkage to achieve high precision and high resistance to abrasion. Due to its properties, Kimya ABS Kevlar is ideal for jigs, fixtures, tolls, and end use parts, such as robotic end effectors and protective gear.
  • Kimya ABS-ESD – This is an ABS material which has been formulated to possess electrostatic discharge (ESD) properties, which protects against electrostatic discharges that can cause damages to electronics systems and create fire and personal safety hazards. Kimya ABS-ESD is a lightweight and rigid material that offers good impact resistance. The material is easy to print, and is ideal for applications that require protection against electrostatic discharge, such as electronics housings and production fixtures.
  • Kimya ABS-EC – Kimya ABS-EC is a new and unique composite material consisting of ABS with the addition of carbon nanotubes, an electrically-active additive. The material allows for the circulation of electrons along its surface, making it electrically-conductive (EC). The material is also resistant to impact, heat, and ageing. Its unique properties open up new applications in the automotive and electronics industry, such as touch sensors.

Kimya ABS Carbon and PETG Carbon are also available for METHOD through MakerBot LABS. Kimya materials can be purchased online.

METHOD is able to print a variety of materials, including ABS, PC-ABS, Nylon 12 Carbon Fiber, ASA, and PETG, as well as a host of materials from partners. The platform’s modularity allows users to easily switch between the six different extruders that MakerBot offers for different material groups and applications. Partners in the MakerBot LABS Materials Development Program include Kimya by ARMOR Group, Polymaker, BASF 3D Printing Solutions, Jabil, LEHVOSS Group, and Mitsubishi Chemical.

For more information, visit www.makerbot.com/method.

About MakerBot

MakerBot, a Stratasys company, is a global leader in the 3D printing industry. The company helps create the innovators of today and the businesses and learning institutions of the future. Founded in 2009 in Brooklyn, NY, MakerBot strives to redefine the standards for 3D printing for reliability, accessibility, precision, and ease-of-use. Through this dedication, MakerBot has one of the largest install bases in the industry and also runs Thingiverse, the largest 3D printing community in the world.

We believe there’s an innovator in everyone, so we make the 3D printing tools that make your ideas matter. Discover innovation with MakerBot 3D printing.

To learn more about MakerBot, visit makerbot.com, the MakerBot blog, Twitter, LinkedIn, or Facebook. Stratasys (parent company of MakerBot) reserves the right to utilize any of the foregoing social media platforms, including the company’s websites, to share material, non-public information pursuant to the SEC’s Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.

MakerBot, MakerBot LABS, MakerBot METHOD, MakerBot METHOD X, and METHOD are trademarks or registered marks of MakerBot Industries, LLC. STRATASYS and SR-30 are trademarks of Stratasys, Inc. All other trademarks are the property of their respective owners.

Note Regarding Forward-Looking Statement

The statements in this press release relating to Stratasys’ and/or MakerBot’s beliefs regarding the benefits consumers will experience from using the Kimya ABS composite materials, MakerBot LABS for METHOD materials, MakerBot LABS Experimental Extruder, and the METHOD platform are forward-looking statements reflecting management’s current expectations and beliefs. These forward-looking statements are based on current information that is, by its nature, subject to rapid and even abrupt change. Due to risks and uncertainties associated with Stratasys’ business, actual results could differ materially from those projected or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the degree of our success at introducing new or improved products and solutions that gain market share; the degree of growth of the 3D printing market generally; the duration of the global COVID-19 pandemic, which, if extensive, may continue to impact, in a material adverse manner, our operations, financial position and cash flows, and those of our customers and suppliers; the impact of potential shifts in the prices or margins of the products that we sell or services that we provide, including due to a shift towards lower-margin products or services; the impact of competition and new technologies; potential further charges against earnings that we could be required to take due to impairment of additional goodwill or other intangible assets; to the extent of our success at successfully consummating acquisitions or investments in new businesses, technologies, products or services; potential changes in our management and board of directors; global market, political and economic conditions, and in the countries in which we operate in particular (including risks related to the impact of coronavirus on our operations, supply chain, liquidity, cash flow and customer orders; costs and potential liability relating to litigation and regulatory proceedings; risks related to infringement of our intellectual property rights by others or infringement of others’ intellectual property rights by us; the extent of our success at maintaining our liquidity and financing our operations and capital needs; the impact of tax regulations on our results of operations and financial condition; and other risk factors set forth under the caption “Risk Factors” in Stratasys’ most recent Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on February 26th, 2020. Readers are urged to carefully review and consider the various disclosures made throughout our 2019 Annual Report and the Report of Foreign Private Issuer on Form 6-K that attaches Stratasys’ unaudited, condensed consolidated financial statements and its review of its results of operations and financial condition, for the quarterly period ended March 31, 2020, which we furnished to the SEC on May 14, 2020, and our other reports filed with or furnished to the SEC, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. Any guidance provided, and other forward-looking statements made, in this press release are made as of the date hereof, and Stratasys and MakerBot undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Bennie Sham

MakerBot

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Hardware Manufacturing Other Manufacturing Other Technology Technology

MEDIA:

Photo
Photo
(Photo: Business Wire)

Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary

Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary

President & CEO Purnanand Sarma Announced as the Recipient of TiE Boston’s 2020 Lifetime Achievement Award

EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19, today announced the recent appointments of Richard Baron to Immunome’s Board of Directors and as Audit Committee Chair, and Sandra Stoneman, Esq. as Chief Legal Officer and Corporate Secretary. The company also today announced that its President and Chief Executive Officer, Purnanand Sarma, Ph.D. is the recipient of TiE Boston’s 2020 Lifetime Achievement Award. The award recognizes individuals who have made invaluable contributions in the fields of science, business and entrepreneurship.

“I am thrilled to welcome Richard and Sandra to the Immunome team as we accelerate our efforts in discovering novel antibodies and advancing our lead programs into the clinic,” said President and CEO, Purnanand Sarma, Ph.D. “The combination of their expertise and experience will be invaluable in supporting Immunome’s growth.” He further stated, “I am also honored to receive TiE Boston’s 2020 Lifetime Achievement Award and very much appreciate the opportunity to continue to work with TiE in driving innovation and fostering next generation entrepreneurs.”

Richard Baron has over 30 years of experience as an advisor to companies in the pharmaceutical, biotechnology and medical device industries and as a Chief Financial Officer. He was previously the Chief Financial Officer of Zynerba Pharmaceuticals (Nasdaq: ZYNE), Globus Medical (NYSE: GMED), Avid Radiopharmaceuticals, Animas Corporation (Nasdaq: PUMP) and others. Baron was a practicing certified public accountant, beginning his career in audit and tax services at Coopers & Lybrand and Arthur Young. He received his B.S. in economics at The Wharton School of the University of Pennsylvania. Baron’s background and experience advising life sciences companies and in finance and accounting added significantly to the Board’s skills in these areas.

Sandra Stoneman, Esq. is a seasoned attorney, with more than 20 years of experience advising high-growth companies in the life sciences and technology sectors. Prior to joining Immunome, Stoneman was an attorney at Duane Morris, leading the Firm’s life sciences practice group. She has received numerous accolades for her transactional work in the life sciences field, including being continuously listed in U.S. News/Best Lawyers, Chambers USA and LMG Life Sciences. Stoneman received her J.D. from Temple University School of Law and her B.A. from the State University of New York at Binghamton.

About Immunome, Inc.

Immunome is a biopharmaceutical company utilizing our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated with an initial focus on oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome’s beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM‐ONC‐01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words “anticipate,” believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “may,” “will,” “could,” “should,” “seek” and similar expressions. Forward-looking statements are based on Immunome’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome’s business, operations, strategy, goals and anticipated milestones, Immunome’s ability to execute on its strategy including with respect to the timing of IND filings, Immunome’s ability to fund operations, as well as those risks and uncertainties set forth more fully under the caption “Risk Factors” in the final prospectus dated October 1, 2020 and filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and elsewhere in Immunome’s filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Investor Contact

Purnanand Sarma, Ph.D.

President and CEO

Immunome, Inc.

[email protected]

Media Contact

Nick Chang

MacDougall

781-235-3060

[email protected]

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Oncology Health Infectious Diseases Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Renesas Strengthens IP License Portfolio with IP Utilities to Facilitate Device Development

Renesas Strengthens IP License Portfolio with IP Utilities to Facilitate Device Development

New Application Packages and Evaluation Kits Jumpstart IP Evaluation for Developers

TOKYO–(BUSINESS WIRE)–
Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today announced the release of IP Utilities – a new series of solutions aimed at simplifying the development of devices incorporating Renesas intellectual property (IP). The new IP Utilities include application packages and evaluation kits, as well as expanding Renesas’ growing portfolio of leading-edge IP licenses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005207/en/

Renesas releases IP Utilities to simplify development of devices (Graphic: Business Wire)

Renesas releases IP Utilities to simplify development of devices (Graphic: Business Wire)

With the emergence of CPUs based on open-source architectures such as RISC-V, the use of licensed IP for device development is becoming more attractive from the cost, time and design risk perspectives. Developing original devices has become very demanding in terms of both the growing number of steps and the time required, due to the need to verify many IP component combinations, such as peripheral functions and application-specific functions. Leveraging Renesas’ extensive manufacturing expertise and the new IP Utilities solutions, developers can confidently shorten the development time for their original semiconductor devices based on Renesas’ highly reliable IP and reduce the time to market.

“Our IP portfolio lineup has grown to include more than 80 offerings since Renesas first entered the IP licensing market in 2018,” said Tetsuya Matsumoto, Vice President, Shared R&D Core IP Division at Renesas.“Where most IP vendors offer only individual IP cores, we are providing developers access to rich IP solutions that includes proven CPUs and peripheral IPs. The introduction of the new IP Utilities opens up opportunities to create new IP markets and further expand our business that benefit from our extensive experience in semiconductor design.”

The new IP Utilities offerings include:

  • Application packages that allow development of original microcontroller (MCU) with a short turnaround time (TAT)

    Developers can take advantage of the application packages to implement application-specific functions as part of MCU development. For example, the 12-Axis Motor Control Package allows MCU developers to implement multi-axis motor control, which can be difficult to support in general-purpose MCU products. The base package includes a CPU, peripheral IPs, and motor control IPs, all capable of 12-axis stepping motor control. Developers may customize the system as desired, for example changing the number of axes, switching to brushless DC motor control or switching to a different CPU.
  • Early adopter kit enabling early evaluation of AI accelerator cores

    Renesas’ early adopter kit allows developers to promote early phase evaluation of the Processing-in-Memory (PIM) AI accelerator IP (Note 1), which achieves superior power efficiency of 8.8 TOPS/W. Support is also available for software development. Developers can use the Raspberry Pi control board to combine PIM functions in a stacked configuration of up to three boards – expanding the scale of inference processing.
  • IP core configuration simplification tools

    Developers can use the new configuration tools to study the specifications of complex IP cores with advanced functionality and optimize their performance in user applications. The first configuration tool is for the PCI Express controller core and enables the user to easily perform simulations involving variables, such as transfer speed, number of lanes, and bus bit width, and easily select the optimal configuration for achieving target performance from over 500,000 variations.
  • TCAM front end library to study product specifications

    Renesas offers a front-end library for the Ternary Content Addressable Memory (TCAM) IP that combines advanced functionality and power efficiency. In addition to the conventional network packet processing field, developers can research new solutions with utilized trial TCAM front-end libraries in user-defined configurations including advanced technologies, such as the 7 nm process.
  • Equivalent EMC design consulting for devices

    The IP Utilities offering includes EMC design consulting based on Renesas’ extensive experience of EMC design work in Renesas devices. By considering EMC design issues upstream in the system development process, for example with regard to pin assignments, board design, and component layout, developers can reduce the burden of noise-countermeasure following manufacture and reduce the iterations to fix.

Renesas plans to expand its lineup of IP Utilities with future offerings such as an evaluation environment for immediate evaluation of Ethernet TSN performance and an evaluation board mounted with an FPGA incorporating CPU cores.

For more information, visit https://www.renesas.com/products/ip-products.html

Note 1: The PIM IP is scheduled for release in 2021.

About Renesas Electronics Corporation

Renesas Electronics Corporation (TSE: 6723) delivers trusted embedded design innovation with complete semiconductor solutions that enable billions of connected, intelligent devices to enhance the way people work and live. A global leader in microcontrollers, analog, power, and SoC products, Renesas provides comprehensive solutions for a broad range of automotive, industrial, infrastructure, and IoT applications that help shape a limitless future. Learn more at renesas.com. Follow us on LinkedIn, Facebook, Twitter, and YouTube.

(Remarks) All registered trademarks or trademarks are the property of their respective owners.

Media Contacts:

Japan

Kyoko Okamoto

Renesas Electronics Corporation

+ 81-3-6773-3001

[email protected]

KEYWORDS: Japan Asia Pacific

INDUSTRY KEYWORDS: Semiconductor Hardware Electronic Design Automation Technology Software

MEDIA:

Logo
Logo
Photo
Photo
Renesas releases IP Utilities to simplify development of devices (Graphic: Business Wire)

Gilead Sciences to Acquire MYR GmbH

Gilead Sciences to Acquire MYR GmbH

Gilead to Acquire Hepcludex, a First-in-Class Entry Inhibitor, for Treatment of Chronic Hepatitis Delta Virus (HDV), Adding Immediate Revenue After Closing of Transaction –

Hepcludex Was Conditionally Approved in Europe in July 2020 Based on Phase 2 Data and Submission for Accelerated Approval in United States is Anticipated in Second Half of 2021

Acquisition Builds on Gilead’s Strength as a Global Leader in Virology and Liver Diseases with Addition of First Marketed Product for Treatment of HDV

FOSTER CITY, Calif. & BAD HOMBURG, Germany–(BUSINESS WIRE)–
Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €300 million (both payments subject to customary adjustments).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005315/en/

The acquisition will provide Gilead with Hepcludex (bulevirtide), which was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020. MYR has since launched Hepcludex in France, Germany and Austria, and continues to prepare for launch in certain other markets throughout 2021. It is expected that this transaction will accelerate the global launch of Hepcludex. Hepcludex is a first-in-class treatment for HDV that blocks viral entry into liver cells through binding to NTCP. It is the first and currently the only medicine conditionally approved for HDV by the EMA, and MYR anticipates submission for accelerated approval in the United States in the second half of 2021. The U.S. Food and Drug Administration (FDA) has granted the medicine both Orphan Drug and Breakthrough Therapy designations for chronic HDV infection.

HDV is the most severe form of viral hepatitis and can have mortality rates as high as 50% within 5 years in cirrhotic patients. HDV occurs only as a co-infection in individuals who have hepatitis B virus (HBV). At least 12 million people worldwide are likely currently co-infected with HDV and HBV. HDV co-infection leads to more serious liver disease than HBV alone and is associated with a faster progression to liver fibrosis, cirrhosis, hepatic decompensation and an increased risk of liver cancer and death. In the United States and Europe, there are collectively more than 230,000 people living with HDV, which remains underdiagnosed globally.

“HDV is a devastating disease with high unmet medical need. With Hepcludex we have the opportunity to address that need with a first-in-class therapy,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “We look forward to working with the team at MYR to realize the full potential of Hepcludex for patients with HDV worldwide. This will build on the work that Gilead has been doing for almost two decades to innovate and improve therapies for viral hepatitis.”

“We are proud of our achievement in bringing Hepcludex from preclinical stage to patients in need within such a short timeframe,” said Dmitry Popov, Chief Executive Officer, MYR GmbH. “We are excited to join Gilead, whose experience in the hepatitis field and global infrastructure will realize the full potential of Hepcludex and provide access to as many patients as possible around the world with this debilitating disease.”

Hepcludex (bulevirtide) is an entry inhibitor that binds to NTCP, an essential HBV and HDV receptor on hepatocytes, blocking the ability of HDV to enter hepatocytes. Bulevirtide has been tested in more than 500 patients in completed and ongoing clinical studies. The benefit of bulevirtide has been demonstrated by an effective reduction of HDV RNA levels and improvement of liver inflammation. In the MYR202 study, which was a controlled, open-label Phase 2 study, 54 of 90 patients treated with bulevirtide plus tenofovir disoproxil fumarate (TDF) had at least a 2 log10 HDV RNA decline or undetectable HDV RNA at week 24 versus 1 of 28 patients given TDF alone. Almost half of patients treated with bulevirtide and TDF also showed a normalization in the blood levels of the liver enzyme ALT, indicating an improvement of liver disease, as compared to 7% of patients who received TDF alone.

In the Phase 2 MYR203 study evaluating a 48-week treatment course of bulevirtide, a further 15 patients were treated with Hepcludex 2mg daily monotherapy for 48 weeks. In this limited dataset, the safety and efficacy profiles were similar to patients treated for 24 weeks in combination with TDF in the MYR202 study. Interim 24-week data from the ongoing Phase 3 study MYR301 of bulevirtide is anticipated in the first half of 2021 and is expected to serve as the basis for filing in the United States.

Terms of the Agreement

Under the terms of the sale and purchase agreement, Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €300 million upon U.S. FDA approval (both payments subject to customary adjustments). After the closing, in addition to enhancing Gilead’s revenue growth, the acquisition of MYR is expected to be neutral to non-GAAP EPS in the first two years after close and moderately accretive thereafter. Closing of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and receipt of merger control approvals in certain European jurisdictions.

Goldman Sachs & Co. LLC is acting as financial advisor to Gilead. UBS Europe SE is acting as financial advisor to MYR. Gibson, Dunn & Crutcher, Mayer Brown LLP, and Flick Gocke Schaumburg are serving as legal counsel to Gilead and Freshfields Bruckhaus Deringer Rechtsanwälte Steuerberater PartG mbB is serving as legal counsel to MYR.

Additional Information

Additional information about the agreement can be found at Gilead’s Investors page at http://investors.gilead.com.

About Hepcludex (bulevirtide)

Hepcludexis the first drug conditionally approved for the treatment of HDV in adults with compensated liver disease in Europe. Hepcludex blocks the NTCP receptor on the surface of hepatocytes and prevents the entry of HBV/HDV into hepatocytes and viral spread within the liver. Hepcludex is administered subcutaneously as monotherapy or in patients being treated with a nucleoside/nucleotide analogue. Hepcludexhas received Orphan Drug Designation for treatment of HDV infection from EMA and from the FDA. Hepcludex has been granted PRIority MEdicines (PRIME) scheme eligibility by EMA for the treatment of HDV infection and Breakthrough Therapy designation by the FDA. Bulevirtide is an investigational agent in the U.S. and outside of the European Economic Area; in these regions the safety and efficacy have not been established.

The most commonly reported serious adverse reaction was an exacerbation of hepatitis after treatment discontinuation, and most commonly reported adverse reactions were an increase in bile salts and injection site reactions. The safety and efficacy of Hepcludex in patients with decompensated cirrhosis have not been established and therefore its use is not recommended. See the Summary of Product Characteristics, which includes contraindications and special warnings and precautions, for further product information, available at www.eua.europa.eu.

About MYR GmbH

MYR GmbH is a private, commercial stage biotechnology company headquartered in Bad Homburg, Germany. The company is dedicated to the development of bulevirtide; bulevirtide is a first-in-class entry inhibitor which binds to the NTCP receptor for HDV and other indications. MYR started operations in 2011 and has been supported by its founders, private and venture capital investors including the High-Tech-Gründerfonds (www.htgf.de/en/). For more information on MYR, please visit the company’s website at www.myr-pharma.com.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Gilead Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of the parties to complete the transaction in a timely manner or at all; the possibility that various closing conditions for the transaction may not be satisfied or waived, including the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; uncertainties relating to the timing or outcome of any filings and approvals relating to the transaction; difficulties or unanticipated expenses in connection with integrating the companies, including the effects of the transaction on relationships with employees, other business partners or governmental entities; the risk that Gilead may not realize the expected benefits of this transaction; the ability of Gilead to advance MYR GmbH’s product pipeline and successfully commercialize Hepcludex; the ability of the parties to initiate and complete clinical trials involving Hepcludex in the currently anticipated timelines or at all; the possibility of unfavorable results from one or more of such trials involving Hepcludex; uncertainties relating to regulatory applications and related filing and approval timelines, including the risk that FDA may not approve Hepcludex for the treatment of HDV in the anticipated timelines or at all, and any marketing approvals, if granted, may have significant limitations on its use; any assumptions underlying any of the foregoing; and other risks and uncertainties detailed from time to time in Gilead’s periodic reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaim any intent to update any such forward-looking statements.

Gilead Contacts:

Monica Tellado, Investors

(650) 522-5132

Marni Kottle, Media

(650) 522-5388

MYR Contact:

Florian Vogel, CCO, MYR GmbH

+49 (0) 6172-49 59 813

KEYWORDS: California Germany Europe United States North America

INDUSTRY KEYWORDS: Biotechnology Infectious Diseases Hospitals Health Pharmaceutical

MEDIA:

Logo
Logo
Logo
Logo

Home Equity Reaches Record Highs: Homeowners Gained Over $1 Trillion in Equity in Q3 2020, CoreLogic Reports

Home Equity Reaches Record Highs: Homeowners Gained Over $1 Trillion in Equity in Q3 2020, CoreLogic Reports

  • The number of mortgages in negative equity fell by 18.3% year over year in Q3 2020
  • Average equity gain of $17,000 per homeowner in Q3 2020 was the highest in over six years

IRVINE, Calif.–(BUSINESS WIRE)–
CoreLogic® (NYSE: CLGX), a leading global property information, analytics and data-enabled solutions provider, today released the Home Equity Report for the third quarter of 2020. The report shows U.S. homeowners with mortgages (which account for roughly 63% of all properties) have seen equity increase by 10.8% year over year, representing a collective equity gain of $1 trillion, and an average gain of $17,000 per homeowner, since the third quarter of 2019. This marks the largest average equity gain since the first quarter of 2014.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005224/en/

CoreLogic Map of Average Year-over-Year Equity Gain per Borrower (Graphic: Business Wire)

CoreLogic Map of Average Year-over-Year Equity Gain per Borrower (Graphic: Business Wire)

Despite the economic impact of the pandemic, home prices soared throughout the summer and fall. Appreciation reached its highest level since 2014 in the third quarter of 2020 as prospective homebuyers continued to compete for the low supply of homes on the market, pushing home equity to record levels. Equity gains are likely to persist over the next several months as strong home-purchase demand is expected to remain high and continue pushing prices up. However, the CoreLogic HPI Forecast shows home prices slowing over the next 12 months as new home construction and more existing for-sale homes ease supply pressures. This could moderate the pace of both home price growth and equity gains.

“Over the past year, strong home price growth has created a record level of home equity for homeowners,” said Dr. Frank Nothaft, chief economist for CoreLogic. “The average family with a home mortgage loan had $194,000 in home equity in the third quarter. This provides an important buffer to protect families if they experience financial difficulties, and is one reason for the generational-low in foreclosure rates reported in September.”

“The housing market has remained a strong pillar in an otherwise tumultuous economic year,” said Frank Martell, president and CEO of CoreLogic. “A sharp rise in demand, spurred by record-low interest rates, continues to bolster homeowner equity. And with many people now spending more time than ever before at home, some homeowners have tapped into their strengthening equity to fund renovations.”

Negative equity, also referred to as underwater or upside down, applies to borrowers who owe more on their mortgages than their homes are currently worth. As of the third quarter of 2020, negative equity share, and the quarter-over-quarter and year-over-year changes, were as follows:

  • Quarterly change: From the second quarter of 2020 to the third quarter of 2020, the total number of mortgaged homes in negative equity decreased by 6.9% to 1.6 million homes or 3% of all mortgaged properties.
  • Annual change: In the third quarter of 2019, 2 million homes, or 3.7% of all mortgaged properties, were in negative equity. This number decreased by 18.3%, or 370,000 properties, in the third quarter of 2020 to 1.6 million mortgaged properties in negative equity.
  • National aggregate value: The national aggregate value of negative equity was approximately $283.3 billion at the end of the third quarter of 2020. This is down quarter over quarter by approximately $2.2 billion, or 0.8%, from $285.5 billion in the second quarter of 2020, and down year over year by approximately $21.4 billion, or 7%, from $304.7 billion in the third quarter of 2019.

Because home equity is affected by home price changes, borrowers with equity positions near (+/-5%) the negative equity cutoff are most likely to move out of or into negative equity as prices change. Looking at the third quarter of 2020 book of mortgages, if home prices increase by 5%, 247,000 homes would regain equity; if home prices decline by 5%, 337,000 would fall underwater.

While national figures continue to reflect a resilient housing market, equity gains varied broadly at the local level. States with strong home price growth and high home prices continued to experience the largest gains in equity. This includes Washington, where homeowners gained an average of $35,800; California, where homeowners gained an average of $33,800 and Massachusetts, where homeowners gained an average of $31,200. Meanwhile, North Dakota, which was hit hard by the pandemic, experienced the lowest annual equity gain (averaging just $5,400) in the third quarter of 2020.

The next CoreLogic Homeowner Equity Report will be released in March 2021, featuring data for Q4 2020. For ongoing housing trends and data, visit the CoreLogic Insights Blog: www.corelogic.com/insights-index.aspx.

Methodology

The amount of equity for each property is determined by comparing the estimated current value of the property against the mortgage debt outstanding (MDO). If the MDO is greater than the estimated value, then the property is determined to be in a negative equity position. If the estimated value is greater than the MDO, then the property is determined to be in a positive equity position. The data is first generated at the property level and aggregated to higher levels of geography. CoreLogic uses public record data as the source of the MDO, which includes more than 50 million first- and second-mortgage liens, and is adjusted for amortization and home equity utilization in order to capture the true level of MDO for each property. Only data for mortgaged residential properties that have a current estimated value are included. There are several states or jurisdictions where the public record, current value or mortgage data coverage is thin and have been excluded from the analysis. These instances account for fewer than 5% of the total U.S. population. The percentage of homeowners with a mortgage is from the 2018 American Community Survey. Data for the previous quarter was revised. Revisions with public records data are standard, and to ensure accuracy, CoreLogic incorporates the newly released public data to provide updated results.

Source: CoreLogic

The data provided is for use only by the primary recipient or the primary recipient’s publication or broadcast. This data may not be re-sold, republished or licensed to any other source, including publications and sources owned by the primary recipient’s parent company without prior written permission from CoreLogic. Any CoreLogic data used for publication or broadcast, in whole or in part, must be sourced as coming from CoreLogic, a data and analytics company. For use with broadcast or web content, the citation must directly accompany first reference of the data. If the data is illustrated with maps, charts, graphs or other visual elements, the CoreLogic logo must be included on screen or website. For questions, analysis or interpretation of the data, contact Valerie Sheets at [email protected]. Data provided may not be modified without the prior written permission of CoreLogic. Do not use the data in any unlawful manner. This data is compiled from public records, contributory databases and proprietary analytics, and its accuracy is dependent upon these sources.

About CoreLogic

CoreLogic (NYSE: CLGX), the leading provider of property insights and solutions, promotes a healthy housing market and thriving communities. Through its enhanced property data solutions, services and technologies, CoreLogic enables real estate professionals, financial institutions, insurance carriers, government agencies and other housing market participants to help millions of people find, buy and protect their homes. For more information, please visit www.corelogic.com.

CORELOGIC and the CoreLogic logo are trademarks of CoreLogic, Inc. and/or its subsidiaries. All other trademarks are the property of their respective owners.

Valerie Sheets

CoreLogic

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Finance Banking Professional Services Residential Building & Real Estate Construction & Property

MEDIA:

Logo
Logo
Photo
Photo
CoreLogic Map of Average Year-over-Year Equity Gain per Borrower (Graphic: Business Wire)
Photo
Photo
CoreLogic Negative Equity Share for Select Metropolitan Areas (Graphic: Business Wire)
Photo
Photo
CoreLogic National Home Equity Distribution by LTV Segment (Graphic: Business Wire)